Climb Bio, Inc.
CLYMHealthcare|Biotechnology|US
$10.29
+1.42 (+16.01%)
DCF Value
$0.49
Tangible Book / Share
$2.85
Cash / Share
$2.57
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07043946 A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia (ITP), ITP | P1P2 | Recruiting | 24 | Open-label | Budoprutug |
| NCT07564596 A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erthematosus | P1P2 | Recruiting | 30 | Open-label | Budoprutug |
| NCT07096843 A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy | Primary Membranous Nephropathy | P2 | Recruiting | 45 | Open-label | budoprutug |
| NCT07011043 A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | P1 | Recruiting | 30 | Open-label | Budoprutug |
| NCT07248865 A Phase 1 Study of CLYM116 in Normal Healthy Volunteers | Healthy Volunteers | P1 | Recruiting | 48 | RCT, Double-blind | CLYM116, Placebo |
| NCT07090655 A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers | Healthy Volunteers | Early P1 | Completed | 30 | RCT, Double-blind | Budoprutug, Placebo |